Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Explores AI Content Marketplace With Media Publishers 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
TEMECULA, Calif., Nov. 16, 2017 -- International Endeavors Corporation (OTC:IDVV) ("IEC") today announced it has received Pink Current Status from OTC Markets as part of the company’s corporate restructure with KUBBY Cryogenics, Inc., subsidiary partner of IEC, and biomedical cannabis research and development firm.
Nate Engel, CEO, stated: “Now that the company is current with OTC Markets, we look forward to greater market liquidity while pursuing the Company’s business restructuring objectives. The Company has already been working with KUBBY Cryogenics to secure several strains of Medical Marijuana to be patented and used in it’s proprietary extraction method that captures the live resins that have medical benefits for a number of ailments, including: cancer, inflammatory disease, epilepsy, brain injury, autism, Alzheimer’s, to name a few. The Company plans to announce the additions to the Board including Steve Kubby as well as several scientific advisors shortly.”
About International Endeavors Corporation
International Endeavors Corporation is a company focused on creating IP related to the Medical Marijuana Industry including biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Nate Engel, President
951-296-1024
